GenVec discontinues pivotal trial of cancer drug TNFerade

03/30/2010 | Reuters

GenVec abandoned a clinical trial of TNFerade after preliminary results showed that the gene therapy reduced the risk of death by about 8% when combined with chemotherapy and radiation in patients with advanced pancreatic cancer compared to standard therapy alone. The biotech firm intends to conduct further analysis of the drug and monitor study participants.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal Electrical Engineer - 14000008LR
San Jose, CA
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Systems Test - V&V Engineer - 14000008LS
San Jose, CA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC